Twist Bioscience Expands AI Drug Discovery Exposure Through Partnership with Lilly TuneLab
Twist Bioscience (NASDAQ:TWST) announced a strategic partnership with Eli Lilly and Company's (NYSE:LLY) platform, Lilly TuneLab. As part of the agreement, Twist will provide antibody characterization data services to support TuneLab’s AI-driven drug discovery efforts, including AbLab—an antibody developability prediction model—and high-throughput wet-lab data for training these models. The collaboration positions Twist as a key player in generating experimental data and offering specialized services within the growing AI-enabled drug discovery ecosystem. While not guaranteeing near-term revenue growth due to lack of disclosed financial terms, it could lead to incremental service demand if TuneLab adoption increases. The partnership also enhances Twist’s credibility by aligning with Lilly's advanced platform. However, there is no assurance that increased AI usage will directly translate into significant revenue for data providers like Twist. Success depends on the effectiveness of these models in generating viable drug candidates and improving development efficiency.
